Company news
Simcere Pharmaceutical Group Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Voluntary announcement - entering into an exclusive promotion services agreement with lynk pharmaceuticals in respect of dermatological indications of zemprocitinib
November 2, 2026
Next Day Disclosure Return
October 27, 2026
Next Day Disclosure Return
October 26, 2026
Next Day Disclosure Return
October 23, 2026
Next Day Disclosure Return
October 22, 2026
Next Day Disclosure Return
October 13, 2026
Next Day Disclosure Return
October 9, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 5, 2026
Notification letter and reply form to non-registered holders: notice of publication of interim report 2026
September 24, 2026
Notification letter and reply form to registered shareholders: notice of publication of interim report 2026
September 24, 2026
2026 Interim report
September 24, 2026
(Revised) Next Day Disclosure Return
September 14, 2026
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
September 1, 2026
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
June 12, 2026
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
January 27, 2026
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
November 10, 2025
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
October 16, 2025
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
June 18, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
June 16, 2025
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
June 26, 2024
Phase II/III clinical trial of Simcere's 3CL-targeting anti-SARS-CoV-2 drug candidate complete all patients enrollment
December 20, 2022
Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc
September 28, 2022
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue
September 5, 2022
Simcere Pharma (2096.HK) Announces a Positive Profit Alert
February 23, 2022
Simcere Pharmaceutical Group: Further announcement profit forecast in relation to disposal of subsidiaries
April 28, 2021
Simcere Pharmaceutical Group: Voluntary announcement in relation to the approval on clinical trial application for the addition of new indications of trilaciclib for injection
April 16, 2021
Change in use of proceeds
April 15, 2021
Simcere Pharmaceutical Group: Voluntary announcement in relation to the clinical trial approval for sim-307 issued by the center for drug evaluation of national medical products administration of prc
April 13, 2021
Resignation of executive director and chief operating officer
March 31, 2021
Simcere Pharmaceutical Group: Revised Terms of Reference of the Strategy Committee
March 25, 2021
Simcere Pharmaceutical Group: Voluntary announcement in relation to the approval of phase iii clinical trial application for addition of new indication for endostar by the national medical products administration of china
March 21, 2021